Design and anticipated outcomes of the eMERGE-PGx project: A multicenter pilot for preemptive pharmacogenomics in electronic health record systems

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 4, 2014, Pages 482-489

  Rasmussen Torvik, L J ^a   Stallings, S C ^b   Gordon, A S ^c   Almoguera, B ^d   Basford, M A ^b   Bielinski, S J ^e   Brautbar, A ^f   Brilliant, M H ^f   Carrell, D S ^g   Connolly, J J ^d   Crosslin, D R ^c   Doheny, K F ^h   Gallego, C J ⁱ   Gottesman, O ^j   Kim, D S ^c   Leppig, K A ^g   Li, R ^k   Lin, S ^f   Manzi, S ^l   Mejia, A R ^j   Pacheco, J A ^a   Pan, V ^a   Pathak, J ^e   Perry, C L ^l   Peterson, J F ^b   Prows, C A ^m   Ralston, J ^g   Rasmussen, L V ^a   Ritchie, M D ⁿ   Sadhasivam, S ^m,o   Scott, S A ^j   Smith, M ^a   Vega, A ^j   Vinks, A A ^m,o   Volpi, S ^k   Wolf, W A ^l,p   Bottinger, E ^j   Chisholm, R L ^a   Chute, C G ^e   Haines, J L ^q   Harley, J B ^o,r,s   Keating, B ^d   Holm, I A ^a,l   Kullo, I J ^e   Jarvik, G P ⁱ   Larson, E B ^g   Manolio, T ^k   McCarty, C A ^t   Nickerson, D A ^c   Scherer, S E ^u   Williams, M S ^v   Roden, D M ^q   Denny, J C ^b,q   more..

^a NORTHWESTERN UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e MAYO CLINIC   (United States)

^f MARSHFIELD CLINIC   (United States)

^g GROUP HEALTH RESEARCH INSTITUTE   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^l BOSTON CHILDREN S HOSPITAL   (United States)

^m CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁿ PENNSYLVANIA STATE UNIVERSITY   (United States)

^o UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^p HARVARD MEDICAL SCHOOL   (United States)

^q VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r UNIVERSITY OF CINCINNATI   (United States)

^s VETERANS AFFAIRS MEDICAL CENTER   (United States)

^t ESSENTIA INSTITUTE OF RURAL HEALTH   (United States)

^u BAYLOR COLLEGE OF MEDICINE   (United States)

^v GEISINGER HEALTH SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGED; CHILD; CLINICAL TRIAL; DNA SEQUENCE; DRUG THERAPY; ELECTRONIC MEDICAL RECORD; FEMALE; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC VARIABILITY; GENOTYPE; HUMAN; KNOWLEDGE BASE; MALE; MIDDLE AGED; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; PHARMACOGENETICS; PHENOTYPE; PILOT STUDY; YOUNG ADULT;

ADOLESCENT; AGED; CHILD; DATABASES, GENETIC; DRUG THERAPY; ELECTRONIC HEALTH RECORDS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOTYPE; HUMANS; KNOWLEDGE BASES; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENOTYPE; PILOT PROJECTS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84921648422     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.137     Document Type: Article

References (47)

1. Green, E.D. & Guyer, M.S.; National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature 470, 204-213 (2011).
2. Collins, F. Opportunities and challenges for the NIH-an interview with Francis Collins. Interview by Robert Steinbrook. N. Engl. J. Med. 361, 1321-1323 (2009).
3. Hamburg, M.A. & Collins, F.S. The path to personalized medicine. N. Engl. J. Med. 363, 301-304 (2010).
4. McBride, C.M., Alford, S.H., Reid, R.J., Larson, E.B., Baxevanis, A.D. & Brody, L.C. Putting science over supposition in the arena of personalized genomics. Nat. Genet. 40, 939-942 (2008).
5. Mardis, E.R. Next-generation sequencing platforms. Annu. Rev. Anal. Chem. (Palo Alto. Calif.). 6, 287-303 (2013).
6. Tennessen, J.A. et al.; Broad GO; Seattle GO; NHLBI Exome Sequencing Project. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337, 64-69 (2012).
7. Gottesman, O. et al.; eMERGE Network. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet. Med. 15, 761-771 (2013).
8. Giacomini, K.M. et al.; Pharmacogenetics Research Network. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin. Pharmacol. Ther. 81, 328-345 (2007).
9. Klein, T.E. et al.; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
10. Perera, M.A. et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 382, 790-796 (2013).
11. Shuldiner, A.R. et al.; Pharmacogenomics Research Network Translational Pharmacogenetics Program Group. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin. Pharmacol. Ther. 94, 207-210 (2013).
12. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 89, 464-467 (2011).
13. McCarty, C.A. et al.; eMERGE Team. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med. Genomics 4, 13 (2011).
14. Kho, A.N. et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J. Am. Med. Inform. Assoc. 19, 212-218 (2012).
15. Kho, A.N. et al. Electronic medical records for genetic research: results of the eMERGE consortium. Sci. Transl. Med. 3, 79re1 (2011).
16. Crosslin, D.R. et al.; Electronic Medical Records and Genomics (eMERGE) Network. Genetic variants associated with the white blood cell count in 13,923 subjects in the eMERGE Network. Hum. Genet. 131, 639-652 (2012).
17. Crosslin, D.R. et al.; CHARGE Hematology Working Group; electronic Medical Records and Genomics (eMERGE) Network. Genetic variation associated with circulating monocyte count in the eMERGE Network. Hum. Mol. Genet. 22, 2119-2127 (2013).
18. Denny, J.C. et al. Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome-and phenome-wide studies. Am. J. Hum. Genet. 89, 529-542 (2011).
19. Shameer, K. et al. A genome-and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects. Hum. Genet. 133, 95-109 (2014).
20. Jeff, J.M. et al. Generalization of Variants identified by genome-wide association studies for electrocardiographic traits in African Americans. Ann. Hum. Genet. 77, 321-332 (2013).
21. Rasmussen-Torvik, L.J. et al. High density GWAS for LDL cholesterol in African Americans using electronic medical records reveals a strong protective variant in APOE. Clin. Transl. Sci. 5, 394-399 (2012).
22. Ritchie, M.D. et al.; Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) QRS Group. Genome-and phenome-wide analyses of cardiac conduction identifies markers of arrhythmia risk. Circulation 127, 1377-1385 (2013).
23. Ding, K. et al. Genetic variants that confer resistance to malaria are associated with red blood cell traits in African-Americans: an electronic medical recordbased genome-wide association study. G3 (Bethesda). 3, 1061-1068 (2013).
24. Kullo, I.J. et al. Complement receptor 1 gene variants are associated with erythrocyte sedimentation rate. Am. J. Hum. Genet. 89, 131-138 (2011).
25. Schildcrout, J.S. et al. An analytical approach to characterize morbidity profile dissimilarity between distinct cohorts using electronic medical records. J. Biomed. Inform. 43, 914-923 (2010).
26. Newton, K.M. et al. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. J. Am. Med. Inform. Assoc. 20, e147-e154 (2013).
27. Peissig, P.L. et al. Importance of multi-modal approaches to effectively identify cataract cases from electronic health records. J. Am. Med. Inform. Assoc. 19, 225-234 (2012).
28. Zuvich, R.L. et al. Pitfalls of merging GWAS data: lessons learned in the eMERGE network and quality control procedures to maintain high data quality. Genet. Epidemiol. 35, 887-898 (2011).
29. Starren, J., Williams, M.S. & Bottinger, E.P. Crossing the omic chasm: a time for omic ancillary systems. JAMA 309, 1237-1238 (2013).
30. Pulley, J.M. et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92, 87-95 (2012).
31. Clayton, E.W. et al.; Consent and Community Consultation Working Group of the eMERGE Consortium. Confronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium. Genet. Med. 12, 616-620 (2010).
32. Hartzler, A. et al. Stakeholder engagement: a key component of integrating genomic information into electronic health records. Genet. Med. 15, 792-801 (2013).
33. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP). Seattle, WA. .
34. Xu, H., Stenner, S.P., Doan, S., Johnson, K.B., Waitman, L.R. & Denny, J.C. MedEx: a medication information extraction system for clinical narratives. J. Am. Med. Inform. Assoc. 17, 19-24 (2010).
35. Savova, G.K. et al. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. J. Am. Med. Inform. Assoc. 17, 507-513 (2010).
36. Denny, J.C. Chapter 13: Mining electronic health records in the genomics era. PLoS Comput. Biol. 8, e1002823 (2012).
37. Johnson, J.A., Elsey, A.R., Clare-Salzler, M.J., Nessl, D., Conlon, M. & Nelson, D.R. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics 14, 723-726 (2013).
38. Farrugia, G. & Weinshilboum, R.M. Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine. Clin. Pharmacol. Ther. 94, 204-206 (2013).
39. Schildcrout, J.S. et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin. Pharmacol. Ther. 92, 235-242 (2012).
40. Green, R.C. et al.; American College of Medical Genetics and Genomics. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15, 565-574 (2013).
41. Rehm, H.L. et al.; Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Commitee. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med. 15, 733-747 (2013).
42. Bielinski, S.J. et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin. Proc. 89, 25-33 (2014).
43. Peterson, J.F. et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet. Med. 15, 833-841 (2013).
44. Van Driest, S.L. et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin. Pharmacol. Ther. 95, 423-431 (2014).
45. Mougey, E.B., Feng, H., Castro, M., Irvin, C.G. & Lima, J.J. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet. Genomics 19, 129-138 (2009).
46. Birdwell, K.A. et al. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients. Pharmacogenet. Genomics 22, 32-42 (2012).
47. Lala, M., Burckart, G.J., Takao, C.M., Pravica, V., Momper, J.D. & Gobburu, J.V. Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridging. J. Pediatr. Pharmacol. Ther. 18, 209-219 (2013).